Metagenomi, Inc. is a biotechnology company focused on the advancement of gene editing technologies for therapeutic applications
With a strong emphasis on leveraging its proprietary genomic tools, the company aims to develop novel treatments for genetic disorders and other complex diseases. Metagenomi's innovative approach combines advanced bioengineering and synthetic biology to create precision therapies that can effectively address a wide range of medical challenges. Through rigorous research and collaboration with leading scientific institutions, Metagenomi is dedicated to transforming the landscape of gene therapy and improving patient outcomes.
Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a drug developer this year.
